Disitamab vedotin in combination with lenvatinib for patients with HER2-positive unresectable locally advanced or metastatic biliary tract cancer: study protocol of a phase II clinical trial
Authors
Jun Xue (ORCID: https://orcid.org/0000-0003-2771-8859)
Dongen Liu (ORCID: https://orcid.org/0009-0000-9019-765X)
G. R. WU
Jing Tang
Zilong Wu
Jinfeng Zhang
Institutions
Union Hospital (HK)
Wuhan Union Hospital (CN)
Huazhong University of Science and Technology (CN)
Beijing Xisike Clinical Oncology Research Foundation
National Natural Science Foundation of China
Science Fund for Distinguished Young Scholars of Hubei Province
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Disitamab vedotin in combination with lenvatinib for patients with HER2-positive unresectable locally advanced or metastatic biliary tract cancer: study protocol of a phase II clinical trial
Jun Xue, Dongen Liu, G. R. WU, Jing Tang et al.
Citations
1 citations
Journal
BMJ Open
Topics
Cholangiocarcinoma and Gallbladder Cancer Studies
Field-Weighted Citation Impact (FWCI)
39.15
article
Disitamab vedotin in combination with lenvatinib for patients with HER2-positive unresectable locally advanced or metastatic biliary tract cancer: study protocol of a phase II clinical trial
Jun Xue, Dongen Liu, G. R. WU, Jing Tang, Zilong Wu, Jinfeng Zhang
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 16(1)
Institutions
Union Hospital (HK), Wuhan Union Hospital (CN), Huazhong University of Science and Technology (CN), Hubei University (CN)
Funders
Beijing Xisike Clinical Oncology Research Foundation, National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Hubei Province